publication date: Sep. 4, 2020
NCI Trials for September 2020
The National Cancer Institute approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I/II – 10382
A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination with Copanlisib in Patients with Metastatic Triple Negative Breast Cancer
Yale University Cancer Center LAO
Phase II – ANBL19P1
A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination with Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma
Children’s Oncology Group
Desai, Ami V.
Phase II – EA6191
The BAMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma
ECOG-ACRIN Cancer Research Group
Phase II/III – NRG-LU007
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Phase III – A011801
The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
Alliance for Clinical Trials in Oncology
O’Sullivan, Ciara C.
Phase III – NRG-GU009
Parallel Phase III Randomized Trials for High Risk Prostate … Continue reading NCI Trials for September 2020
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.